Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus

Makimura, M; Miyake, Shingo; Akino, Nobuko; Takamori, Koichi; Matsuura, Yoshiharu; Miyamura, Tatsuo; Saito, Izumu

doi:10.1016/0264-410x(95)00161-s

Cited by 43 publications

(21 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The replication-defective recombinant adenoviruses expressing the HCV structural proteins (core, E1, and E2; Adex1SR3ST) and the HCV nonstructural proteins (NS3, NS4, and NS5A; Adex1CA3269) were previously described (33,62). The wild-type adenovirus lacking the insert (Adex1w) was used as a negative control.…”

Section: Methodsmentioning

confidence: 99%

Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice

Matsui

Moriya

Belladonna

et al. 2004

J Virol

View full text Add to dashboard Cite

CD8ϩ cytotoxic T lymphocytes (CTLs) recognize virus-derived peptides in association with major histocompatibility complex class I molecules on the surface of antigen-presenting cells and kill the virus-infected target cells. There are a number of evidences showing that CTLs play a central role in the clearance of pathogenic viruses (67). In case of hepatitis C virus (HCV) infection, vigorous HCV-specific CTL responses existed in the persons resolving acute HCV infection (27). In the experimental model, chimpanzees who cleared HCV generated strong CTL but poor antibody responses, whereas other chimpanzees developing chronic hepatitis generated much weaker CTL response (12). Thus, spontaneous resolution of HCV is likely to be associated with HCV-specific CTLs rather than neutralizing antibodies (12,18,27,58). However, Ͼ60% of HCV-infected individuals turn out to have chronic hepatitis (1). Chronic HCV hepatitis eventually progresses to cirrhosis and hepatocellular carcinoma (53). In the chronic stage, HCVspecific CTLs are detectable in both peripheral blood and liver, but the precursor frequency of HCV-specific CTLs is extremely low (27,50,51). Therefore, enhancement of HCVspecific CTL induction in HCV-infected individuals should be considered to be a strategy to clear the virus. DNA vaccination has been proven to be a useful strategy for inducing both humoral and cellular immune responses (19). DNA vaccine safely mimics the effect of live, attenuated virusbased vaccine to generate a long-lasting CTL response. However, the efficiency of DNA vaccine is sometimes quite low and, therefore, several modifications have been attempted in recent years (19). Thus far, the most successful protocol of DNA immunization for CTL induction is likely to be a consecutive immunization involving priming with plasmid DNA and boosting with recombinant virus (2,24,35,43,54). The rationale behind this strategy is that DNA priming elicits low-level but persistent immunity, followed by strong boosting with virus encoding the same recombinant antigen as the DNA encodes. This regimen of the consecutive immunization has been proven to be efficient for CTL induction by many groups (2,24,35,37,43,54). Recently, McConkey et al. (37) have shown that the prime-boost immunization induced high frequencies of antigen-specific T-cell responses to malaria antigen and displayed partial protection in humans.Interleukin-12 (IL-12) is a heterodimeric proinflammatory cytokine formed by a 35-kDa light chain (p35) and a 40-kDa heavy chain (p40) (57). This cytokine is a dominant factor in the differentiation of T helper type 1 (Th1) cells and plays an essential role in a link between innate and adaptive immunities (60). Recently, two novel polypeptides, p19 (42) and p28 (48), have been identified by searching the databases with a computationally derived profile of IL-6. These factors do not show

show abstract

Section: Methodsmentioning

confidence: 99%

Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice

Matsui

Moriya

Belladonna

et al. 2004

J Virol

View full text Add to dashboard Cite

show abstract

“…Anti-E1/E2 antibodies were measured by using recombinant E1/E2 proteins expressed in insect cells as described previously. 16,17 Neutralization of Binding Assay. For the NOB assay, 1 µg of the E2 protein was mixed with serial dilution of sera and incubated for 30 minutes at 37°C.…”

Section: Methodsmentioning

confidence: 99%

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C

et al. 1998

View full text Add to dashboard Cite

show abstract

“…Thus, effort has been invested in defining HCV CTL epitopes and designing vaccine constructs (85)(86)(87)(88)(89)(90). Such approaches to HCV vaccine development include the use of DNA plasmids (90,91), recombinant viral vectors expressing HCV antigens (91)(92)(93), and HCV viruslike particles (94,95). To improve on the ability of the wild-type viral sequence to induce T cell immunity, the amino acid sequence of epitopes has been modified to increase affinity for the HLA molecule to make the epitopes more potent vaccines (known as epitope enhancement) (88).…”

Section: Hepatitis C Virusmentioning

confidence: 99%

Progress on new vaccine strategies against chronic viral infections

Berzofsky¹,

Ahlers²,

Janik³

et al. 2004

J. Clin. Invest.

101

View full text Add to dashboard Cite

Among the most cost-effective strategies for preventing viral infections, vaccines have proven effective primarily against viruses causing acute, self-limited infections. For these it has been sufficient for the vaccine to mimic the natural virus. However, viruses causing chronic infection do not elicit an immune response sufficient to clear the infection and, as a result, vaccines for these viruses must elicit more effective responses -quantitative and qualitative -than does the natural virus. Here we examine the immunologic and virologic basis for vaccines against three such viruses, HIV, hepatitis C virus, and human papillomavirus, and review progress in clinical trials to date. We also explore novel strategies for increasing the immunogenicity and efficacy of vaccines.

show abstract

Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus

Cited by 43 publications

References 34 publications

Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice

Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C

Progress on new vaccine strategies against chronic viral infections

Contact Info

Product

Resources

About